Description
LOXO-195 is a second-generation TRK inhibitor shown to be active against NTRK resistant mutations, including solvent-front substitutions. In preclinical species, LOXO-195 showed high oral exposure and exhibited favorable absorption, distribution, metabolism, and excretion properties.